[The antioxidant probucol as a regulator of the intensity of free-radical lipid peroxidation processes in the blood of patients with coronary atherosclerosis].
Two series of studies were made to assess probucol medicines (lipomal, "Alkaloid"; fenbutol "Akrikhin") effect on clinical symptoms, lipid metabolism, primary and secondary products of lipid peroxidation, activity of antioxidant enzymes (superoxide dismutase, glutathione peroxidase) in atherosclerotic patients with hyperlipidemia type IIA and IIB. In both series probucol reduced frequency of anginal attacks, content of total cholesterol and LDL cholesterol. HDL cholesterol remained unchanged or reduced insignificantly. Lipoperoxides and malonic dialdehyde levels in plasma progressively lowered against activation of antioxidant enzymes. These biochemical parameters returned to initial values within 3 months since the drug discontinuation. It is evident that antiatherogenic effect of probucol is due to indirect activation of natural defense systems responsible for enzymic detoxication of active oxygen forms and lipoperoxides rather than to direct interaction of this synthetic antioxidant with lipid radicals.
Tikhaze
A K
AK
Lankin
V Z
VZ
Mikhin
V P
VP
Revenko
V M
VM
Lupanov
V P
VP
D000975:Antioxidants / Q000627:therapeutic use*; D002908:Chronic Disease; D003324:Coronary Artery Disease / Q000097:blood* / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D005609:Free Radicals / Q000097:blood; D005979:Glutathione Peroxidase / Q000097:blood / Q000187:drug effects; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy; D015227:Lipid Peroxidation / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood / Q000188:drug therapy; D011341:Probucol / Q000627:therapeutic use*; D013482:Superoxide Dismutase / Q000097:blood / Q000187:drug effects
D000975:Antioxidants; D005609:Free Radicals; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D011341:Probucol